Letrovena (Letrozole)

Letrozole selectively blocks the aromatase enzyme (CYP19A1), which converts androgens into estrogens. By inhibiting this conversion, circulating estrogen levels fall dramatically, depriving estrogen‑dependent breast cancer cells of the growth signal they require, thereby slowing or halting tumor progression.

The specific dose of Letrovena is determined by the prescribing physician based on the patient’s clinical condition, treatment stage, and tolerability. Dosage regimens are individualized and should follow the prescriber’s written instructions; no standard dose is provided here.

Letrovena is classified as Pregnancy Category X, meaning it is contraindicated during pregnancy because it can cause fetal harm. It is also not recommended for breastfeeding mothers, as letrozole may be excreted in breast milk and could affect the infant.

To order Letrovena, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

The primary alternative to letrozole is another aromatase inhibitor such as anastrozole, or the selective estrogen receptor modulator tamoxifen. Letrozole generally provides more potent estrogen suppression than tamoxifen and is often preferred for postmenopausal patients, while anastrozole offers a similar efficacy profile with comparable safety.

Letrovena tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the container tightly closed and out of reach of children. No refrigeration is required for this oral formulation.

Letrovena is taken orally, usually once daily, with or without food, as directed by the prescriber. The tablet should be swallowed whole with a glass of water. Patients should follow the exact dosing schedule provided by their healthcare professional.

Serious risks include severe bone loss leading to osteoporosis or fractures, cardiovascular events such as thromboembolism or myocardial infarction, and liver dysfunction manifested by elevated liver enzymes or hepatitis. Patients should be monitored regularly for these conditions, and any new symptoms reported promptly.

Letrovena should not be used by pregnant or breastfeeding women, premenopausal patients, individuals with severe hepatic impairment, or patients with known hypersensitivity to letrozole or any excipients in the tablet. Clinicians must assess each patient’s medical history before initiating therapy.